- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Type 2 diabetes mellitus |
|---|
|
| Obesity/Overweight |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
In general, the frequency, type, and severity of adverse events in adolescents and in children 10 years of age and older was similar to what was observed in adult patients. Vomiting occured twice as often in adolescents as compared to adults.
The number of confirmed hypoglycemic episodes in children was higher with liraglutide (0.58 events/patient year) compared with placebo (0.29 events/patient year). In children treated with insulin prior to a confirmed hypoglycemic episode, the number was higher with liraglutide (1.82 events/patient year) compared with placebo (0.91 events/patient year). No severe hypoglycemic episodes occurred in the liraglutide-treated group.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Biguanides | ||
|---|---|---|
| A10BA02 | ||
| Sulfonylureas | ||
|---|---|---|
| A10BB01 | ||
| Combinations of oral blood glucose lowering drugs | ||
|---|---|---|
| A10BD20 | ||
| Glucagon-like peptide-1 (GLP-1) analogues | ||
|---|---|---|
| A10BJ05 | ||
| A10BJ01 | ||
| Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ||
|---|---|---|
| A10BK01 | ||
| A10BK03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Novo Nordisk A/S, SmPC Victoza (EU/1/09/529) Rev 21, 11-02-2021, www.geneesmiddeleninformatiebank.nl
- Novo Nordisk A/S , SmPC Saxenda (EU/1/15/992/001-003) 02-06-2021, www.geneesmiddeleninformatiebank.nl
- Novo Nordisk A/S, SmPC Saxenda (EU/1/15/992/001-003) Rev 19; 31-07-2025, www.ema.europa.eu
- Novo Nordisk A/S, SmPC Victoza (EU/1/09/529) Rev 25; 20-02-2025, www.ema.europa.eu
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
